ES2308861T3 - Metodo para determinar la susceptibilidad a desarrollar sepsis y compuestos terapeuticos para el tratamiento e la sepsis. - Google Patents

Metodo para determinar la susceptibilidad a desarrollar sepsis y compuestos terapeuticos para el tratamiento e la sepsis. Download PDF

Info

Publication number
ES2308861T3
ES2308861T3 ES99972008T ES99972008T ES2308861T3 ES 2308861 T3 ES2308861 T3 ES 2308861T3 ES 99972008 T ES99972008 T ES 99972008T ES 99972008 T ES99972008 T ES 99972008T ES 2308861 T3 ES2308861 T3 ES 2308861T3
Authority
ES
Spain
Prior art keywords
allele
sepsis
gene
protein
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99972008T
Other languages
English (en)
Spanish (es)
Inventor
Francesco S. Di Giovine
Gordon W. Duff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of ES2308861T3 publication Critical patent/ES2308861T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES99972008T 1998-10-30 1999-11-01 Metodo para determinar la susceptibilidad a desarrollar sepsis y compuestos terapeuticos para el tratamiento e la sepsis. Expired - Lifetime ES2308861T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US183850 1998-10-30
US09/183,850 US6251598B1 (en) 1998-10-30 1998-10-30 Methods for diagnosing sepsis

Publications (1)

Publication Number Publication Date
ES2308861T3 true ES2308861T3 (es) 2008-12-01

Family

ID=22674558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99972008T Expired - Lifetime ES2308861T3 (es) 1998-10-30 1999-11-01 Metodo para determinar la susceptibilidad a desarrollar sepsis y compuestos terapeuticos para el tratamiento e la sepsis.

Country Status (10)

Country Link
US (2) US6251598B1 (enExample)
EP (1) EP1127168B1 (enExample)
JP (1) JP2002533096A (enExample)
AT (1) ATE403745T1 (enExample)
AU (1) AU779772B2 (enExample)
CA (1) CA2346960A1 (enExample)
DE (1) DE69939269D1 (enExample)
ES (1) ES2308861T3 (enExample)
IL (1) IL142438A0 (enExample)
WO (1) WO2000037679A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
AU2001263373A1 (en) * 2000-09-20 2002-04-02 Genaissance Pharmaceuticals, Inc. Haplotypes of the il1b gene
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
KR20050034584A (ko) * 2001-10-05 2005-04-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물
EP1463745A4 (en) * 2001-11-19 2007-11-07 Interleukin Genetics Inc FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
MXPA05005073A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
MXPA05005072A (es) * 2002-11-12 2005-07-22 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
CA2505921A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
WO2005038427A2 (en) * 2003-06-05 2005-04-28 Medical Gene Center Ltd. Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses
CN1882705A (zh) * 2003-10-06 2006-12-20 诺瓦提斯公司 遗传多态性用于预测药物诱导肝脏毒性的用途
EP1725574A4 (en) * 2004-03-04 2008-10-29 Univ British Columbia THROMBOMODULIN (THBD) HAPLOTYPES AS RESULTS INDICATORS FOR PATIENTS
EP1723160A4 (en) * 2004-03-04 2008-04-23 Univ British Columbia FORECAST OF PATIENT STATUS EVOLUTION USING TOLL-RECEPTOR 2 (TLR-2) HAPLOTYPES
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
RU2286154C2 (ru) * 2005-02-17 2006-10-27 Владимир Алексеевич Шатров Способ лечения воспалительных заболеваний головного мозга
US8293521B2 (en) 2005-03-30 2012-10-23 Shimadzu Corporation Method of dispensing nonvolatile liquid in reaction vessel and reaction vessel processing apparatus
BRPI0609302A2 (pt) 2005-04-15 2011-10-11 Becton Dickinson Co métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
WO2010070136A2 (en) * 2008-12-19 2010-06-24 Centre de Recherche Public de la Santé Novel caviidae allergens and uses thereof
EP2676675B1 (en) 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
CA3011363A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
CA2081774A1 (en) 1990-05-01 1991-11-02 John Stephen Haskill Interleukin-1 antagonist and uses thereof
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE4408890A1 (de) 1994-03-16 1995-09-21 Knoll Ag Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
AU2213697A (en) 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
IL135957A0 (en) 1997-11-07 2001-05-20 Interleukin Genetics Inc Diagnostics and therapeutics for chronic obstructive airway disease
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Also Published As

Publication number Publication date
AU779772B2 (en) 2005-02-10
US20010034032A1 (en) 2001-10-25
AU3995600A (en) 2000-07-12
IL142438A0 (en) 2002-03-10
US6251598B1 (en) 2001-06-26
CA2346960A1 (en) 2000-06-29
EP1127168B1 (en) 2008-08-06
EP1127168A2 (en) 2001-08-29
ATE403745T1 (de) 2008-08-15
US6551785B2 (en) 2003-04-22
DE69939269D1 (de) 2008-09-18
WO2000037679A3 (en) 2001-01-11
WO2000037679A2 (en) 2000-06-29
JP2002533096A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
ES2308861T3 (es) Metodo para determinar la susceptibilidad a desarrollar sepsis y compuestos terapeuticos para el tratamiento e la sepsis.
ES2261239T3 (es) Diagnostico y terapia para la osteoporosis.
ES2431671T3 (es) El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
KR20080077207A (ko) 심혈관 질환용 진단제 및 치료제
US20080254476A1 (en) il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
MXPA02008487A (es) Diagnosticos y terapeutica del glaucoma.
WO2001016377A9 (en) Diagnostics and therapeutics for osteoporosis
US7723028B2 (en) Diagnostics and therapeutics for osteoporosis
US20090023147A1 (en) Diagnostics and therapeutics for osteoporosis
US8105775B2 (en) IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU4183700A (en) Prediction of risk of interstitial lung disease
ES2356167T3 (es) Método de diagnóstico y terapia para enfermedades asociadas con un haplotipo inflamatorio il-1.
HK1093757B (en) Diagnostic for osteoporosis